FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Targeted Oncology4d
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...
Medical Xpress4d
FDA expands use of breast cancer drug Kisqali
Kisqali reduced the risk of a breast cancer coming back by 25% after three years when given along with standard treatments, which can include chemotherapy, surgery and radiation followed by ...
Zacks.com on MSN1d
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
NBC New York5d
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
(Nikki Odum) After she had a double mastectomy, chemotherapy and radiation, her doctor, Denise Yardley, asked if she wanted to join the clinical trial for Kisqali. “It was a no-brainer for me.
Yahoo4d
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
Kisqali reduced the risk of a patient’s breast cancer coming back by 25% after three years when given in addition to standard treatments, which can include chemotherapy, surgery and radiation ...